ABSTRACT: Effect of Raloxifene on Breast Cancer Cell Ki67 and     Apoptosis     [09/17/2001; Cancer Epidemiology, Biomarkers and Prevention] Purpose: Raloxifene is a selective estrogen receptor (ER) modulator approved for prevention and treatment of postmenopausal osteoporosis. This is an exploratory study of raloxifene in primary breast cancer patients. Conclusion: In this exploratory trial, 60 mg/day raloxifene showed a significant antiproliferative effect in ER-positive breast cancer, demonstrated by the decrease in Ki67, with no effect in ER-negative cancer. This provides support for raloxifene having a breast cancer preventive effect in postmenopausal women. Investigators from multiple institutions including Royal Marsden NHS Trust in London, England, the European Institute of Oncology in Milan, Italy, and Eli Lilly and Company in Indianapolis, Indiana, United States, studied postmenopausal women with stage I or II primary breast cancer. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.